Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives $24.35 Consensus PT from Analysts

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has earned a consensus rating of “Hold” from the eighteen analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $24.3529.

TNDM has been the subject of several research reports. Robert W. Baird set a $30.00 price target on shares of Tandem Diabetes Care and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Citigroup raised their target price on shares of Tandem Diabetes Care from $16.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, December 11th. Truist Financial set a $24.00 price objective on shares of Tandem Diabetes Care and gave the stock a “hold” rating in a research report on Thursday, December 18th. TD Cowen initiated coverage on shares of Tandem Diabetes Care in a research report on Tuesday, January 27th. They issued a “buy” rating and a $25.00 price objective on the stock. Finally, Wells Fargo & Company lifted their target price on shares of Tandem Diabetes Care from $13.00 to $14.00 and gave the stock an “equal weight” rating in a report on Friday, November 7th.

Institutional Trading of Tandem Diabetes Care

Hedge funds have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue increased its position in Tandem Diabetes Care by 1.4% during the 4th quarter. State of Alaska Department of Revenue now owns 38,676 shares of the medical device company’s stock worth $849,000 after buying an additional 523 shares during the period. ProShare Advisors LLC grew its stake in shares of Tandem Diabetes Care by 4.6% in the fourth quarter. ProShare Advisors LLC now owns 13,185 shares of the medical device company’s stock valued at $290,000 after acquiring an additional 579 shares in the last quarter. Natixis Advisors LLC increased its position in Tandem Diabetes Care by 1.1% during the fourth quarter. Natixis Advisors LLC now owns 57,021 shares of the medical device company’s stock worth $1,253,000 after acquiring an additional 617 shares during the period. Amalgamated Bank increased its position in Tandem Diabetes Care by 3.5% during the third quarter. Amalgamated Bank now owns 19,617 shares of the medical device company’s stock worth $238,000 after acquiring an additional 657 shares during the period. Finally, LPL Financial LLC boosted its holdings in Tandem Diabetes Care by 1.8% in the 4th quarter. LPL Financial LLC now owns 39,590 shares of the medical device company’s stock valued at $870,000 after purchasing an additional 716 shares during the period.

Tandem Diabetes Care Stock Down 5.7%

Shares of Tandem Diabetes Care stock traded down $1.12 during trading on Thursday, reaching $18.54. The stock had a trading volume of 232,812 shares, compared to its average volume of 1,223,724. The company has a current ratio of 2.44, a quick ratio of 1.90 and a debt-to-equity ratio of 2.33. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -6.08 and a beta of 1.68. The stock has a fifty day moving average price of $21.10 and a two-hundred day moving average price of $16.84. Tandem Diabetes Care has a 52 week low of $9.98 and a 52 week high of $35.12.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.